Patent ID: 11931373
Assignee: UNIVERSITY OF SOUTH FLORIDA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 13:
14. A composition comprising an Aha1 inhibitor for treatment of a tauopathy in a subject,
wherein the composition comprises 3-(3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamido)-8-methoxy-2-oxo-2H-chromen-7-yl acetate (KU-177); and
one or more pharmaceutically acceptable carriers;
wherein the Aha1 inhibitor is in a form suitable for systemic administration, parenteral administration, or oral administration;
wherein the Aha1 inhibitor that is in the form suitable for systemic administration comprises about 0.01% to about 50% of the Aha1 inhibitor and about 50% to about 99.99% of the one or more pharmaceutically acceptable carriers;
wherein the Aha1 inhibitor that is in the form suitable for parenteral administration comprises about 0.1% to 10% of the Aha1 inhibitor and about 90% to about 99.9% of the one or more pharmaceutically acceptable carriers; and
wherein the Aha1 inhibitor that is in the form suitable for oral administration comprises about 5% to about 50% of the Aha1 inhibitor and about 50% to about 95% of the one or more pharmaceutically acceptable carriers.